F-13640
- Generic Name
- F-13640
Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia
- First Posted Date
- 2021-12-08
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Neurolixis SAS
- Target Recruit Count
- 27
- Registration Number
- NCT05148884
- Locations
- 🇸🇪
Karolinska University Hospital, Solna, Stockholm, Sweden
🇸🇪Sahlgrenska Hospital, Gothenburg, Sweden
🇸🇪ASC Torsplan, Stockholm, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath